Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:
“OptiTROP-Lung03 published on The BMJ: sacituzumab tirumotecan (sac-TMT) versus docetaxel for previously treated EGFR-mutated advanced NSCLC.
- sac-TMT vs docetaxel
- ORR: 45% vs 16%
- PFS: 6.9 vs 2.8 months
- OS: NR, HR=0.49
(data also presented at ASCO25).”
Title: Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial
Authors: Wenfeng Fang, Xingya Li, Qiming Wang, Xiangjiao Meng, Wei Zheng, Longhua Sun, Wenxiu Yao, Wu Zhuang, Yun Fan, Minglei Zhuo, Yongzhong Luo, Zhiye Zhang, Xia Song, Runxiang Yang, Jiacheng Yang, Xiaoping Jin, Yina Diao, Junyou Ge, Li Zhang
Read The Full Article at The BMJ.
More posts featuring Raffaele Colombo.